Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report issued on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, May 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.67.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $0.32 on Thursday. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.67. The company’s 50 day moving average price is $0.52 and its two-hundred day moving average price is $0.61. The firm has a market cap of $66.82 million, a PE ratio of -0.17 and a beta of 1.24.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. During the same period in the prior year, the company earned $0.12 EPS. On average, research analysts expect that Sangamo Therapeutics will post -0.55 EPS for the current year.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Wasatch Advisors LP lifted its stake in shares of Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after acquiring an additional 7,734,400 shares during the last quarter. Acadian Asset Management LLC raised its position in Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sangamo Therapeutics during the first quarter worth about $331,000. Finally, Golden State Equity Partners increased its stake in shares of Sangamo Therapeutics by 21.0% in the fourth quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 34,960 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.